Yahoo Web Search

  1. Health Canada plans to suspend the license for Allergan Plc's Biocell breast implant due to the risk of a rare cancer linked to such implants, the regulator said in a notice to ...

  2. Allergan's AMD Drug Lowers Inflammation in Phase III Study

    Zacks via Yahoo FinanceApr 03 14:00 PM

    MAPLE, a 28 week open-label study, used a modified manufacturing process to test an optimized 12-week formulation of abicipar in nAMD patients Following the improved manufacturing process, it ...

  3. If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Allergan ...

  4. Will Ironwood Suffer From Dependence on Linzess' Progress?

    Zacks via Yahoo FinanceApr 05 14:34 PM

    We remind investors that Ironwood co-develops and co-commercializes Linzess and equally shares Linzess U.S. collaboration profits/losses as well as development costs with Allergan AGN ...

  5. The FDA grants Fast Track designation to help the development and a faster review of drugs, which treat serious and unmet medical conditions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

  6. Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics

    Zacks via Yahoo FinanceApr 01 20:57 PM

    Novartis AG NVS announced that it will acquire IFM Tre, a subsidiary of IFM Therapeutics LLC. The acquisition will add a broad portfolio of immunomodulatory medicines, focused on developing ...

  7. This week Pfizer PFE and Teva TEVA gained marketing approval from the European Commission for their new medicines. While Pfizer gained approval for its new lung cancer medicine, Vizimpro, Teva's ...

  8. Editas (EDIT) Inks Cross Licensing Agreement with BlueRock

    Zacks via Yahoo FinanceApr 04 19:39 PM

    Editas Medicine, Inc. EDIT inked a research and cross licensing agreement with BlueRock Therapeutics, LP, to combine their respective genome editing and cell-therapy technologies to discover ...

  9. Wynn's backtracking illustrates how media leaks of deal talks can test the resolve of potential acquirer. Crown shares jumped as much as 22 percent on the news to A$14.37, close to the $A14.75 ...

  10. Alkermes Reports Positive Data From Schizophrenia Study

    Zacks via Yahoo FinanceApr 10 14:46 PM

    Alkermes plc ALKS announced positive top-line results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a six-month phase IIIb study evaluating ...